All three are FDA-approved, all three work by the same basic mechanism, and all three are widely available. So why does the choice actually matter — and how does a provider make it?
If you have spent any time researching injectable wrinkle treatments, you have almost certainly encountered the three major names: Botox, Dysport, and Xeomin. You have probably also encountered a version of the same reassurance from every source — that they all work the same way, the differences are minor, and the injector matters more than the product. That last part is genuinely true. But the rest of it sells the question short. The differences between these three neurotoxins are real, clinically meaningful in specific contexts, and worth understanding before you sit down for a consultation.
Botox (onabotulinumtoxinA, manufactured by Allergan/AbbVie), Dysport (abobotulinumtoxinA, manufactured by Galderma), and Xeomin (incobotulinumtoxinA, manufactured by Merz) all belong to the same pharmacological class: botulinum toxin type A. All three work by temporarily blocking the nerve signals that tell targeted facial muscles to contract. When those muscles cannot contract, the overlying skin cannot fold, and dynamic wrinkles — the lines caused by repeated facial movement — relax and soften.
All three are FDA-approved for cosmetic use, all three have well-established safety records when administered by trained providers, and all three are reversible in the sense that results fade naturally as the product clears the system over three to four months. This shared foundation is why experienced injectors say the product matters less than the skill behind it. A technically precise treatment with any of the three will outperform a technically poor treatment with the "best" one.
That said, the molecular differences between the three products have real clinical implications — particularly for patients with specific skin concerns, treatment histories, or anatomical considerations.
Botox®
Allergan · onabotulinumtoxinA
FDA approval
2002 (cosmetic); broadest approval set of the three
Onset
3–7 days; peak at ~2 weeks
Duration
3–4 months typical
Diffusion
Moderate; precise for targeted areas
Formulation
Active toxin with complexing proteins
Dysport®
Galderma · abobotulinumtoxinA
FDA approval
2009 (cosmetic glabellar lines)
Onset
24–48 hours; faster than Botox
Duration
3–4 months; some data suggest slightly longer for certain areas
Diffusion
Higher; spreads more broadly per injection point
Formulation
Active toxin with complexing proteins; smaller molecular structure
Xeomin®
Merz · incobotulinumtoxinA
FDA approval
2011 (cosmetic glabellar lines)
Onset
3–5 days
Duration
~3 months; some patients report longer
Diffusion
Lower; stays close to injection site
Formulation
"Naked" toxin — no complexing accessory proteins
Of all the variables above, diffusion — how far the product spreads from the injection point through surrounding tissue — has the most direct bearing on clinical outcomes and provider decision-making. A 2020 review published in the journal Toxins examined the biophysical properties of the three major neurotoxins and confirmed that Dysport diffuses more broadly than Botox, which diffuses more broadly than Xeomin. This is not a flaw in any product; it is a property that makes each one better suited to different treatment scenarios.
For large, flat muscle groups like the forehead, broader diffusion is often desirable — it allows comprehensive coverage with fewer injection points, which can reduce discomfort and bruising risk. Dysport's diffusion profile makes it a natural fit here. For small, precise muscles near the eyes or around the mouth, where unwanted spread could affect adjacent muscles and produce drooping or asymmetry, tighter diffusion is preferable. Xeomin's smaller spread radius gives a technically skilled injector more control in these anatomically complex areas. Botox sits comfortably in the middle and has the widest base of clinical evidence supporting its use across virtually every treatment zone.
The product choice is not a preference — it is a clinical decision based on your facial anatomy, the area being treated, your treatment history, and your goals. A provider making that decision without examining you first is not making it correctly.
Xeomin's defining characteristic is the absence of accessory proteins surrounding the active botulinum toxin molecule. Botox and Dysport both include complexing proteins that stabilize the formulation. These proteins are inert for most patients, but over time and with repeated treatment — particularly in patients receiving neurotoxin injections every three months for a decade or more — a small percentage of patients develop neutralizing antibodies against these proteins, which can gradually reduce treatment effectiveness.
Because Xeomin contains only the purified active molecule, it presents no protein target for antibody development of this type. A study published in the Journal of Neural Transmission found lower rates of secondary treatment failure in long-term neurotoxin patients who switched to protein-free formulations. For most patients, this distinction is not clinically significant. For patients who have noticed their neurotoxin treatments wearing off faster than they once did, Xeomin is a legitimate and evidence-supported option worth discussing with a provider.
Xeomin also does not require refrigeration prior to reconstitution, which is a minor logistical point but one that some practices cite when discussing product freshness and handling consistency.
One of the most important practical points for patients to understand is that units are not equivalent across the three products. Botox and Xeomin are dosed roughly comparably unit-for-unit, but Dysport requires approximately two and a half to three times as many units to achieve an equivalent clinical effect. This is not because Dysport is weaker — it is because the unit of biological activity is defined differently in each product's manufacturing process.
Clinics that quote neurotoxin pricing "per unit" without specifying which product are not giving you comparable numbers. A clinic offering Botox at $12 per unit and Dysport at $5 per unit may be charging nearly identical effective prices when dosing is factored in. Any transparent practice will explain this clearly at consultation. Practices that do not are either uninformed or structuring their pricing to obscure the comparison.
A well-prepared patient makes a better consultation. Before your appointment, it helps to know what you are looking to treat, whether you have had neurotoxin treatments before and how they responded, and whether you have any known sensitivities or allergies. At the consultation itself, these are the questions worth asking:
The considerations above — product selection, diffusion profiles, dosing equivalence, antibody risk in long-term patients — require a provider who has not only technical injection skill but genuine familiarity with the clinical literature and the properties of each product. This is not a guarantee that comes with any particular title. It comes from supervised training, ongoing education, and the kind of practice volume that builds real pattern recognition in facial anatomy.
For patients in the South Bay Los Angeles area looking for this standard of care, Skin Works Medical Spa — a physician-supervised practice in Torrance — offers all three major neurotoxins alongside Jeuveau, with transparent per-unit pricing published online and complimentary consultations where providers explain their product recommendation before any treatment is agreed upon. It is a practical example of what an informed, no-pressure neurotoxin consultation looks like.
The right product for you exists. Finding it is mostly a matter of finding a provider who takes the question seriously enough to answer it with your specific anatomy in mind rather than defaulting to whatever they stock most. To explore your options and get a personalized recommendation, you can review the full neurotoxin services and current pricing at Skin Works Medical Spa's neurotoxin treatment page before booking.
— • —
References & further reading: U.S. Food and Drug Administration, approval histories for Botox (2002), Dysport (2009), and Xeomin (2011) (fda.gov); Kerscher M et al., “Comparison of the spread of three botulinum toxin type A preparations,” Toxins (2020); Dressler D, “Comparing Botulinum Toxin A preparations: differences in clinical effects and immunological properties,” Journal of Neural Transmission (2016); American Society of Plastic Surgeons, 2023 Plastic Surgery Statistics Report; Carruthers J & Carruthers A, “Botulinum toxin type A: history and current cosmetic use in the upper face,” Seminars in Cutaneous Medicine and Surgery (2001); Galderma, Dysport prescribing information; Merz Pharmaceuticals, Xeomin prescribing information; Allergan, Botox Cosmetic prescribing information.
